arrow
B

Bárbara Adamo

University of Barcelona
H指数:41
被引数:7,985

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Genomic and clinical features in young women with estrogen receptor-positive, HER2-negative breast cancer

雌激素受体阳性、HER2阴性乳腺癌年轻女性的基因组与临床特征

2025-09-240
PREAI
Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial

帕博西利和曲妥珠单抗用于HER2阳性转移性乳腺癌:SOLTI-1303-PATRICIA试验A组和B组的最终总生存结果

2025-09-010
OAAI
Preoperative Radiotherapy-Induced Molecular and Immune Modulation in Early-Stage Breast Cancer: Results from the YOUNGSTER Trial

术前放疗诱导的分子和免疫调控在早期乳腺癌中的作用:YOUNGSTER试验的结果

2025-08-050
OA
Considerations for hereditary breast and ovarian cancer syndrome molecular diagnosis: experience from the clinical practice
2025-02-240
PRE
Clinical and molecular characteristics of early-stage triple-negative breast cancer (eTNBC) patients with germline pathogenic variants in homologous recombination repair genes

携带同源重组修复基因胚系致病性变异的早期三阴性乳腺癌(eTNBC)患者的临床与分子特征

2024-09-010
PRE
Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer
2024-07-112
OAAI
Randomized Phase II trial evaluating three antidiarrhoeal prophylaxis strategies in patients with HER2+/HR+ early breast cancer treated with extended adjuvant neratinib (DIANER GEICAM/2018-06)
2024-05-020
PRE
Targeting PAM50 HER2-Enriched intrinsic subtype with enzalutamide in hormone receptor- positive/HER2-negative (HR+/HER2-) advanced breast cancer: results of the SOLTI-1502 ARIANNA trial
2024-05-020
PRE
A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies

早期三阴性乳腺癌 (TNBC) 的14基因b细胞免疫特征: 七项研究的汇总分析

2024-04-013
OAAI
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer
2023-09-0118
OAAI
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2-breast cancer

TROPION-Breast01: Datopotamab deruxtecan与化疗在不能手术或转移性HR /HER2-breast癌中的应用

2023-06-3033
OA
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer (vol 7, 1, 2021)
2023-04-292
OAAI
SOLTI-1910: Predicting olaparib sensitivity in patients with unresectable locally advanced/metastatic HER2-negative breast cancer with BRCA1/2, PALB2, RAD51C/D mutations or HRD by the RAD51 test: RADIOLA TRIAL
2023-03-010
PRE
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer
2023-03-0123
OAAI
Clinico-Pathological and Molecular Characterization of HER2-Enriched Breast Tumors Independently of HER2 Status
2023-03-010
PRE